Alnylam Pharmaceuticals, Inc. (ALNY) Given New $98.00 Price Target at Needham & Company LLC

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its price target lifted by Needham & Company LLC from $68.00 to $98.00 in a report published on Tuesday. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the stock. Jefferies Group LLC reissued a buy rating and issued a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, June 22nd. Piper Jaffray Companies reissued an overweight rating and issued a $126.00 price objective (up previously from $116.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, June 21st. BidaskClub raised shares of Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Tuesday, June 13th. ValuEngine raised shares of Alnylam Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 13th. Finally, Chardan Capital set a $110.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Monday, June 12th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals has an average rating of Buy and an average target price of $76.03.

Shares of Alnylam Pharmaceuticals (ALNY) traded up 0.18% during trading on Tuesday, reaching $79.97. 1,082,066 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $84.18. The company’s market capitalization is $6.89 billion. The stock has a 50-day moving average of $67.47 and a 200-day moving average of $51.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The business had revenue of $19 million during the quarter, compared to analyst estimates of $22.91 million. During the same period in the previous year, the company earned ($1.21) EPS. Alnylam Pharmaceuticals’s revenue was up 160.3% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals will post ($5.29) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://sleekmoney.com/alnylam-pharmaceuticals-inc-alny-given-new-98-00-price-target-at-needham-company-llc/1947162.html.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Michael Mason sold 9,375 shares of the stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Insiders have sold a total of 64,125 shares of company stock worth $4,325,000 over the last quarter. 4.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Manhattan Co. acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $135,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $148,000. Westpac Banking Corp acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $202,000. Prudential Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $215,000. Finally, Nisa Investment Advisors LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $256,000. Hedge funds and other institutional investors own 89.27% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/alnylam-pharmaceuticals-inc-alny-given-new-98-00-price-target-at-needham-company-llc/1947162.html

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *